
Biogen Relocating to MIT Development in Cambridge
Biogen Inc. will relocate its headquarters to MIT’s new Kendall Square development after leasing 580,000 square feet in the first new lab building at Kendall Common.
Biogen Inc. will relocate its headquarters to MIT’s new Kendall Square development after leasing 580,000 square feet in the first new lab building at Kendall Common.
Two Boston office towers and a newly-completed Kendall Square research center lead the list of nine Massachusetts properties the Trump administration has slated for sale.
Biogen is reportedly in negotiations to lease up to 500,000 square feet as the first tenant at MIT’s redevelopment of the Volpe Center property in Cambridge.
The purchase marks a key milestone in the university’s plans to build eight buildings totaling over 3 million square feet of development in the heart of the state’s innovation hub.
Local legends to the contrary, Cambridge never truly stood a chance to host NASA’s “Mission Control” for its many space exploration missions. But the consolation prize turned into a mess that, nonetheless, cleared the way for today’s Kendall Square.
MIT’s redevelopment of the Volpe Center property still includes plans for the tallest building in Cambridge – but well short of the 500 feet allowed by zoning.
MIT’s redevelopment of the Volpe Center property will include 1,400 housing units, including a 50-story tower and 1.7 million square feet of commercial space, a project that MIT says will propel Kendall Square’s tech- and life science-fueled economic hub to the next level.
Massachusetts Institute of Technology has agreed to pay $750 million for the 14-acre Volpe Center site in Cambridge’s Kendall Square, which it plans to redevelop into a large commercial and residential campus.
Already set to build a 1.8-million-square-foot development in Kendall Square, the Massachusetts Institute of Technology will get the first chance to redevelop the federal government’s 14-acre Volpe Center property at 55 Broadway.